Integer (NYSE:ITGR) Issues FY24 Earnings Guidance

Integer (NYSE:ITGR) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $5.01-5.43 for the period, compared to the consensus EPS estimate of $5.31. The company issued revenue guidance of 1.74-1.77 billion, compared to the consensus revenue estimate of $1.76 billion. Integer also updated its FY 2024 guidance to 5.010-5.430 EPS.

Integer Stock Performance

NYSE ITGR traded down $12.02 during trading on Thursday, hitting $111.25. The company’s stock had a trading volume of 1,606,681 shares, compared to its average volume of 339,607. The company has a quick ratio of 1.71, a current ratio of 2.80 and a debt-to-equity ratio of 0.64. The firm has a 50 day moving average price of $112.91 and a 200 day moving average price of $99.57. The firm has a market cap of $3.73 billion, a P/E ratio of 41.36, a price-to-earnings-growth ratio of 1.63 and a beta of 1.10. Integer has a 52 week low of $69.40 and a 52 week high of $123.99.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 EPS for the quarter, topping the consensus estimate of $1.34 by $0.05. The company had revenue of $413.15 million for the quarter, compared to the consensus estimate of $409.04 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.11 EPS. Equities research analysts forecast that Integer will post 5.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ITGR. Bank of America upgraded Integer from a neutral rating to a buy rating and boosted their price objective for the company from $105.00 to $135.00 in a research report on Monday, April 15th. Benchmark boosted their price objective on Integer from $105.00 to $130.00 and gave the company a buy rating in a research report on Thursday, March 28th. CL King began coverage on Integer in a research report on Thursday, March 14th. They set a buy rating and a $137.00 price objective on the stock. Finally, KeyCorp boosted their price objective on Integer from $123.00 to $139.00 and gave the company an overweight rating in a research report on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus target price of $120.50.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.